INVOKANA®: the first SGLT2i approved for initiation in adults with T2D and an eGFR as low as 30 who have DKD,* established CVD, or are in need of glycemic control1-4

INVOKANA dosing guidance.
INVOKANA dosing guidance.

Increase dosage to 300 mg/day in patients with an eGFR ≥60 who need additional glycemic control.1

INVOKANA® is not recommended and is likely to be ineffective for glycemic control in adults with T2D with an eGFR <30. INVOKANA® is contraindicated in patients on dialysis.1

eGFR is measured in mL/min/1.73 m2.
*With albuminuria >300 mg/day.
†In patients with DKD and albuminuria >300 mg/day.
‡In patients with established CVD.
CV=cardiovascular; CVD=cardiovascular disease; DKD=diabetic kidney disease; ESKD=end-stage kidney disease; HHF=hospitalization for heart failure; MI=myocardial infarction; SGLT2i=sodium-glucose co-transporter 2 inhibitor; T2D=type 2 diabetes.

For more information on dosing and administration, please refer to the full Prescribing Information.

References: 1. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Jardiance® [prescribing information]. Ridgefield, CT: Boehringer lngelheim Pharmaceuticals, Inc. 3. Farxiga® [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. 4. Steglatro® [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.